ArticleBMC health services research2025
Effects of physician-led medication reconciliation on the outcomes of outpatients utilizing the PharmaCloud system.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTaiwan introduced PharmaCloud, a system designed to streamline access to comprehensive medication records from various healthcare settings. Despite its potential, the impact of physician-led medication reconciliation (MR) utilizing PharmaCloud on outpatient outcomes remains unclear. This study aims to address this gap by evaluating the effectiveness of PharmaCloud-enabled MR in improving patient outcomes.
methodsWe collected data from outpatients with major polypharmacy (≥ 10 medications) between May 19, 2019, and April 18, 2020, comparing those who received MR with those who did not. Outcomes including total medical expenditures, ED visits, hospitalizations, mortality rate, and number of medications were compared between the two cohorts over a 12-month follow-up period.
resultsThe study enrolled 209 patients with MR and 9,053 patients without MR. Patients who received MR were older, had lower body mass index, took more medications, and had a higher prevalence of hypertension, cerebrovascular disease, chronic kidney disease, and mental disorder. After 12 months of follow-up, patients who received MR had a higher proportion of reduced medications (adjusted odds ratio: 1.4; 95% confidence interval: 1.0 - 2.0), but also had more ED visits in the first 12 months compared to those who did not receive MR. The study did not find any significant differences in total medical expenditures, hospitalizations, and mortality rates between the two cohorts.
conclusionsThe model reduced medication use. Further research, including prospective designs, pharmacist involvement, and evaluations of reduced complications from fewer medications, is needed to better clarify patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.